1. Home
  2. BMRA vs CVKD Comparison

BMRA vs CVKD Comparison

Compare BMRA & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biomerica Inc.

BMRA

Biomerica Inc.

N/A

Current Price

$2.37

Market Cap

8.2M

Sector

Health Care

ML Signal

N/A

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$8.25

Market Cap

20.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMRA
CVKD
Founded
1971
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2M
20.7M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
BMRA
CVKD
Price
$2.37
$8.25
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$32.00
AVG Volume (30 Days)
21.5K
43.2K
Earning Date
01-13-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$4,884,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.08
$8.12
52 Week High
$10.16
$22.90

Technical Indicators

Market Signals
Indicator
BMRA
CVKD
Relative Strength Index (RSI) 44.11 37.75
Support Level $2.43 $9.55
Resistance Level $2.67 $12.50
Average True Range (ATR) 0.12 1.03
MACD 0.03 0.13
Stochastic Oscillator 27.06 16.26

Price Performance

Historical Comparison
BMRA
CVKD

About BMRA Biomerica Inc.

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Share on Social Networks: